Article
Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.
Virology journal - 14 Feb 2013
Hoffmann Luísa, Ramos Juliene Antonio, Souza Elizabeth Valentin de, Araújo Ramos Ana Lucia de, Villela-Nogueira Cristiane Alves, Urményi Turán Péter, Tanuri Amilcar, Rondinelli Edson, Silva Rosane
Abstract excerpt
UNLABELLED: About sixty thousand new cases of Hepatitis C virus (HCV) infection are recorded in Brazil each year. These cases are currently treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) with an overall success rate of 50%. New compounds for anti-HCV therapy targeted to the HCV NS3 protease are being developed and some already form the components of licensed therapies. Mapping NS3 protease...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.